Table 1.

Change in fatty acid content for the 34 subjects who completed the trial

Median values
Percent of total fatty acid content
Tissue/lipid compartment fatty acid componentBaseline6 moa6.5 mobAt FNA2c (relative change)P (Wilcoxon) for baseline to FNA2d
Erythrocyte PLsN = 34N = 33N = 24N = 34
AA12.710.310.010.0 (−22%)<0.001
EPA0.392.661.661.84 (340%)<0.001
DHA2.505.134.884.88 (80%)<0.001
EPA+DHA:AA ratio0.220.830.660.69 (193%)<0.001
Plasma PLsN = 34N = 33N = 24N = 34
AA9.98.69.28.9 (−15%)<0.001
EPA0.733.400.880.93 (74%)<0.001
DHA2.335.053.894.23 (90%)<0.001
EPA+DHA:AA ratio0.261.140.540.62 (118%)<0.001
Plasma TAGsN = 34N = 33N = 24N = 34
AA1.761.461.521.54 (−18%)0.0071
EPA0.261.210.280.43 (71%)0.0034
DHA0.371.950.760.94 (151%)<0.001
EPA+DHA:AA ratio0.351.970.770.99 (214%)<0.001
Breast TAGsN = 34N = 34N = 34
AA0.410.38 (12%)0.31
EPA0.0330.097 (261%)<0.001
DHA0.0770.16 (133%)<0.001
EPA+DHA:AA ratio0.240.67 (130%)<0.001
Breast PLsN = 34N = 34N = 34
AA1.701.24 (−6%)0.057
EPA0.0400.051 (19%)0.37
DHA0.140.15 (15%)0.23
EPA+DHA:AA ratio0.180.31 (55%)0.017

NOTE: Erythrocyte Phosholipids (PLs), Plasma PLs and Triacylglycerides (TAGs), and Breast Aspirate PLs and TAGs.

  • aFasting blood collected within 24 hours of discontinuation of drug, after a nominal 6 months of intervention.

  • bSecond fasting blood specimen collected the same day as RPFNA which was a median of 14 days following drug discontinuation.

  • cThe change in values represents change at the time of the RPFNA which for 1/3 of participants was within 24 hours of last dose and for approximately 2/3 was a median of 14 days after last dose.

  • dP-values < 0.05 are indicated in bold.